Menu
Search
|

Menu

Close
X

Stemline Therapeutics Inc STML.OQ (NASDAQ Stock Exchange Capital Market)

17.75 USD
+0.15 (+0.85%)
As of Feb 23
chart
Previous Close 17.60
Open 17.70
Volume 70,007
3m Avg Volume 73,841
Today’s High 17.80
Today’s Low 17.15
52 Week High 17.98
52 Week Low 6.35
Shares Outstanding (mil) 28.97
Market Capitalization (mil) 514.25
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
1
FY16
1
FY15
1
EPS (USD)
FY17
-2.012
FY16
-2.151
FY15
-2.150
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
429.40
8.35
Price to Book (MRQ)
vs sector
6.77
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
0.00
15.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-84.77
13.63
Return on Equity (TTM)
vs sector
-84.95
15.39

EXECUTIVE LEADERSHIP

Ivan Bergstein
Chairman of the Board, President, Chief Executive Officer, Since 2003
Salary: $535,613.00
Bonus: $401,709.00
Kenneth Hoberman
Chief Operating Officer, Since 2013
Salary: $428,490.00
Bonus: $214,245.00
David Gionco
Chief Accounting Officer, Vice President - Finance, Since 2014
Salary: $294,587.00
Bonus: $147,293.00
Ron Bentsur
Independent Director, Since 2009
Salary: --
Bonus: --
Eric Dobmeier
Independent Director, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

750 Lexington Ave
NEW YORK   NY   10022-1200

Phone: +1646.5022310

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

SPONSORED STORIES